Oncology, Haematology and Respiratory Diseases Department, University Hospital of Modena, Modena, Italy.
Br J Cancer. 2011 Mar 29;104(7):1079-84. doi: 10.1038/bjc.2011.43. Epub 2011 Mar 8.
In patients with colorectal liver metastases (CLM) R0 resection significantly improves overall survival (OS).
In this report, we present the results of a phase II trial of FOLFOX6+bevacizumab in patients with non-optimally resectable CLM. Patients received six cycles of FOLFOX6+ five of bevacizumab. Patients not achieving resectability received six additional cycles of each. A PET-CT was performed at baseline and again within 1 month after initiating treatment.
From September 2005 to July 2009, 21 patients were enrolled (Male/Female: 15/6; median age: 65 years). An objective response (OR) was documented in 12 cases (57.1%; complete responses (CRs): 3, partial response (PR): 9); one patient died from toxicity before surgery. Thirteen patients underwent radical surgery (61.9%). Three (23%) had a pathological CR (pCR). Six patients (46.1%) experienced minor postsurgical complications. After a median 38.8-month follow-up, the median OS was 22.5 months. Patients achieving at least 1 unit reduction in Standard uptake value (SUV)max on PET-CT had longer progression-free survival (PFS) (median PFS: 22 vs 14 months, P=0.001).
FOLFOX6+bevacizumab does not increase postsurgical complications, yields high rates of resectability and pCR. Early changes in PET-CT seem to be predictive of longer PFS.
在结直肠癌肝转移（CLM）患者中，RO 切除显著改善了总生存期（OS）。
在本报告中，我们报告了 FOLFOX6+贝伐单抗治疗非最佳可切除 CLM 患者的 II 期试验结果。患者接受了六周期的 FOLFOX6+五周期的贝伐单抗治疗。未达到可切除性的患者接受了另外六周期的每种药物治疗。在基线和开始治疗后 1 个月进行了 PET-CT 检查。
从 2005 年 9 月至 2009 年 7 月，共纳入 21 例患者（男/女：15/6；中位年龄：65 岁）。12 例患者（57.1%）有客观反应（OR）；1 例患者因毒性死亡而未能手术。13 例患者接受了根治性手术（61.9%）。3 例（23%）有病理完全缓解（pCR）。6 例患者（46.1%）发生轻微术后并发症。中位随访 38.8 个月后，中位 OS 为 22.5 个月。PET-CT 上标准摄取值（SUV）max 至少降低 1 个单位的患者具有更长的无进展生存期（PFS）（中位 PFS：22 与 14 个月，P=0.001）。
FOLFOX6+贝伐单抗不会增加术后并发症，可提高切除率和 pCR。PET-CT 的早期变化似乎可预测更长的 PFS。
